HIV Diagnostics Testing Market Size
HIV Diagnostics Testing Market is Predicted to reach at a CAGR of 6.3% during the forecast period (2026-2033).
HIV diagnostics are used to detect the human immunodeficiency virus in saliva, serum, or urine. HIV diagnostics aids in detecting antibodies, RNA, and antigens.
HIV Diagnostics Testing Market Scope
| Metrics | Details |
| Market CAGR | 6.3% |
| Segments Covered | By Product, By Test Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
HIV Diagnostics Testing Market Dynamics
The factors influencing the global HIV diagnostics market are the increasing demand for HIV diagnostics, and the growing prevalence of HIV is expected to drive the market growth.
The increasing demand for HIV diagnostics is expected to drive market growth in the forecast period
The increasing awareness about HIV is expected to drive the demand for HIV diagnostics testing. For instance, India's AIDS Control Program is widely regarded as a success story worldwide. The National AIDS Control Programme (NACP) is being implemented as a comprehensive programme for HIV/AIDS prevention and control in India. Over time, the emphasis has shifted from raising awareness to behaviour change, from a national response to a more decentralized response, and increased involvement of NGOs and PLHIV networks to increased involvement of PLHIV networks.
Coordinated action is urgently needed in low- and middle-income countries (LMICs) with the highest HIV burden to ensure that the ambitious 90-90-90 HIV treatment targets set by the Joint United Nations Programme on HIV and AIDS are met. The targets anticipate that by 2020, 90 percent of people living with HIV will be aware of their status, 90 percent of those diagnosed with HIV will begin antiretroviral therapy (ART), and 90 percent of those receiving ART will have long-term viral suppression. Furthermore, the CDC recommends that everyone between 13 and 64 in the United States get tested for HIV at least once.
The drawbacks associated with HIV diagnostics testing is expected to hamper the market growth
The window period is one of the most serious issues with HIV testing (the time between a person being infected with HIV and their body producing enough antibodies for a test to detect). A negative test result could indicate that someone was recently infected with HIV. A positive test result can sometimes be a 'false positive,' leading the person to believe they have HIV when they do not. A negative test result could be a 'false negative,' implying that the person believes they do not have HIV when they do. The cost of testing is also one major reason expected to hamper the market. For instance, HIV testing is extremely expensive. It puts a strain on healthcare budgets in areas where resources are scarce. Except for blood transfusion services, where testing is required, the benefits of testing must be carefully considered. In addition, despite having enough trained counselors, the hospital lacks funds to cover the cost of testing kits, and the supply is unreliable.
HIV Diagnostics Testing Market Segment Analysis
By test type, the antibody tests segment is expected to dominate the market
HIV antibodies are detected in blood or saliva by the Antibody test. When bacteria or viruses enter the body, the immune system produces antibodies. After 3–12 weeks of infection, an HIV antibody test can determine if the person is positive. This can take several weeks or longer for the immune system to produce antibodies against HIV. With the kits, the patient can perform an HIV antibody test in the privacy of their own home. The majority of rapid and self-tests are antibody tests. In general, antibody tests using blood from a vein can detect HIV sooner than tests using blood from a finger prick or oral fluid.
Furthermore, on September 30th, 2020, Roche launched the Elecsys HIV Duo immunoassay in the United States. This test can detect an acute HIV infection earlier than current methods by measuring the HIV p24 antigen (the virus) and anti-HIV antibodies.
HIV Diagnostics Testing Market Geographical Analysis
North America region is expected to hold the largest market share in the global HIV diagnostics testing market
The presence of key players, the high prevalence of HIV/AIDS in the region, and established healthcare infrastructure are some of the key factors expected to drive the market in this region. Furthermore, advantageous government initiatives and an increase in research collaborations. The CDC in the United States recommends routine HIV screening in healthcare settings for all adults aged 13 to 64, with at least annual repeat screening for those at higher risk.
HIV Diagnostics Testing Market Competitive Landscape
The global HIV diagnostics testing market is highly competitive with mergers, collaborations, and product launches. Some of the key players in the market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Danaher Corporation, Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Hologic Inc., JOYSBIO (Tianjin) Biotechnology Co., Ltd., and Bio-Rad Laboratories
Recent Development-
- February 2026: Abbott Laboratories expanded its Alinity m HIV-1 assay portfolio with enhanced viral load monitoring capabilities, improving sensitivity for early-stage detection and supporting decentralized laboratory settings, as highlighted in its diagnostics segment updates.
- January 2026: Roche Diagnostics introduced workflow automation upgrades to its cobas HIV-1/2 testing systems, enabling higher throughput and reduced turnaround time for large-scale screening programs in hospital laboratories.
- December 2025: Siemens Healthineers strengthened its immunoassay portfolio by enhancing HIV antigen/antibody combination testing on the Atellica platform, focusing on improving diagnostic accuracy in early infection detection.
